Bio-Techne Corporation

$63.03

+$3.38 (+5.67%)

Jan 5, 2026

Price History (1Y)

Analysis

Bio-Techne Corporation is a healthcare company within the biotechnology industry. With a market capitalization of $9.82 billion and revenue of $1.22 billion in the trailing twelve months (TTM), it operates on a significant scale with approximately 3100 employees. The financial health of Bio-Techne indicates moderate profitability, with gross margins at 66.8%, operating margins at 16.9%, and profit margins at 6.4%. The company's returns on equity and assets stand at 3.8% and 6.3%, respectively. Its balance sheet features $144.96 million in cash and $394.47 million in debt, equating to a debt-to-equity ratio of 20.07. Bio-Techne's valuation metrics include a price-to-earnings (P/E) ratio of 121.21 on a TTM basis and a forward P/E of 29.17. The company has reported revenue growth of -1.0% year-over-year, with earnings growth at 14.3%. The dividend yield is 54.0%, and the payout ratio stands at 65.3%.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Visit website →

Key Statistics

Market Cap
$9.82B
P/E Ratio
121.21
52-Week High
$79.28
52-Week Low
$46.01
Avg Volume
1.82M
Beta
1.47
Dividend Yield
54.00%

Company Info

Exchange
NMS
Country
United States
Employees
3,100